1/4/2019 PTI-801 - DrugBank
PTI-801
IDENTIFICATION
Name PTI-801
Accession Number DB05300
Type Small Molecule
Groups Investigational
Description PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is o en associated with repeat use of oxycodone.
Synonyms Not Available
International/Other Brands
Oxytrex
Categories Not Available
UNII https://www.drugbank.ca/drugs/DB05300 1/7 1/4/2019 PTI-801 - DrugBank
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES Not Available
PHARMACOLOGY
Indication Investigated for use/treatment in addictions, osteoarthritis, and pain (acute or chronic).
Pharmacodynamics
Not Available
Mechanism of action
PTI-801 is a novel form of oxycodone that minimizes the abuse and drug dependence that is
o en associated with oxycodone and other narcotic painkillers. The goal of developing PTI-801 is to ensure the safety of patients who have a legitimate medical need to treat severe chronic https://www.drugbank.ca/drugs/DB05300 2/7 1/4/2019 y p PTI-801g - DrugBank pain with a narcotic painkiller, and to protect the public from the consequences of abuse.
Absorption
Not Available
Volume of distribution
Not Available
Protein binding Not Available
Metabolism Not Available
Route of elimination Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available
https://www.drugbank.ca/drugs/DB05300 3/7 1/4/2019 PTI-801 - DrugBank
INTERACTIONS
Drug Interactions
Not Available
Food Interactions Not Available
REFERENCES
General References
1. Webster LR: Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83. [PubMed:17685875]
External Links
PubChem Substance
347910063
CLINICAL TRIALS
Clinical Trials
Search
PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓ 1 Recruiting Treatment Cystic Fibrosis (CF) 1
1 Recruiting Treatment Cystic Fibrosis (CF) / Healthy Volunteer - 2 Complete / Healthy Volunteers
Showing 1 to 2 of 2 entries ‹ ›
PHARMACOECONOMICS
https://www.drugbank.ca/drugs/DB05300 4/7 1/4/2019 PTI-801 - DrugBank Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available
PROPERTIES
State
Solid
Experimental Properties Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available
SPECTRA
Mass Spec (NIST)
Not Available
Spectra https://www.drugbank.ca/drugs/DB05300il bl 5/7 1/4/2019 PTI-801 - DrugBank Not Available
TAXONOMY
Classification
Not classified
Drug created on November 18, 2007 11:23 / Updated on November 02, 2018 06:09
About About DrugBank
DrugBank Blog
Wishart Research Group
Terms of Use Privacy Policy
Support
FAQ
Help Email Support
Commercial Products API Pricing API Docs
Data Licenses Support
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is
leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe https://www.drugbank.ca/drugs/DB05300 6/7 1/4/2019 PTI-801 - DrugBank Design & Innovation Inc.
https://www.drugbank.ca/drugs/DB05300 7/7